ART detection in 299 HIV-positive voluntary blood donations collected in the United States from September 2015 through December 2017 and 300 infection-nonreactive donations collected from September through November 2018
| HIV blood screening results . | HIV-positive donors at TTIMS blood centers during period* . | Samples tested for ARVs . | ARVs detected n (%) . | Estimated days since last ARV dose, n (row %) . | ||
|---|---|---|---|---|---|---|
| 1 d ago . | 2 d ago . | 3 d ago . | ||||
| HIV negative | — | 300 | 0 | |||
| HIV positive | 463 | 299 | 46 (15.4)† | 31 (67.4) | 12 (26.1) | 3 (6.5) |
| NAT yield (NAT reactive, serology nonreactive | 11 | 0 | — | — | — | — |
| NAT and serology reactive | 398 | 252 | 5 (2.0) | 4 (80.0) | 1 (20.0) | 0 |
| Serology reactive | 54 | 47 | 41 (87.3) | 27 (65.9) | 11 (26.8) | 3 (7.3) |
| HIV blood screening results . | HIV-positive donors at TTIMS blood centers during period* . | Samples tested for ARVs . | ARVs detected n (%) . | Estimated days since last ARV dose, n (row %) . | ||
|---|---|---|---|---|---|---|
| 1 d ago . | 2 d ago . | 3 d ago . | ||||
| HIV negative | — | 300 | 0 | |||
| HIV positive | 463 | 299 | 46 (15.4)† | 31 (67.4) | 12 (26.1) | 3 (6.5) |
| NAT yield (NAT reactive, serology nonreactive | 11 | 0 | — | — | — | — |
| NAT and serology reactive | 398 | 252 | 5 (2.0) | 4 (80.0) | 1 (20.0) | 0 |
| Serology reactive | 54 | 47 | 41 (87.3) | 27 (65.9) | 11 (26.8) | 3 (7.3) |